Neumora Therapeutics (NMRA) Liabilities and Shareholders Equity (2022 - 2026)

Neumora Therapeutics has reported Liabilities and Shareholders Equity for 5 years, with the latest figure at $153.9 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 40.07% year-over-year to $153.9 million; the trailing twelve-month figure through Mar 2026 stood at $746.6 million (down 43.9% YoY), and the FY2025 full-year result was $191.0 million, down 39.73% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $153.9 million, down from $191.0 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $544.7 million in Q3 2023, with the low at $153.9 million in Q1 2026.
• Average Liabilities and Shareholders Equity over 5 years is $332.9 million, with a median of $334.8 million recorded in 2024.
• Year-over-year, Liabilities and Shareholders Equity increased 16.41% in 2023 and slumped 49.56% in 2025.
• Tracing NMRA's Liabilities and Shareholders Equity over 5 years: stood at $426.2 million in 2022, then increased by 16.41% to $496.2 million in 2023, then sank by 36.12% to $317.0 million in 2024, then sank by 39.73% to $191.0 million in 2025, then dropped by 19.46% to $153.9 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $153.9 million (Q1 2026), $191.0 million (Q4 2025), and $177.8 million (Q3 2025), per Business Quant data.

Peer Comparison